Risk Engine
Every patient gets a 0–100 score built from explainable feature contributions: demographics, symptoms, comorbidities, imaging, procedures, pathology, treatment, response, and follow-up. Configure thresholds per use case to route patients into clinic, imaging, research, urgent review, or tumor board workflows.
Total scored: 14,999 patients.
Use-case thresholds
Clinic referral
Surface to clinic for new-patient triage
1,070patients
Imaging escalation
Order pancreas-protocol CT/MRI for further workup
888patients
Research inclusion
Eligible for research cohorts
780patients
Urgent review
Same-week physician review
700patients
Tumor board
Auto-routed to multidisciplinary review
400patients
Score distribution
Patient counts by 10-point risk-score bucket. Tier zones are color-shaded (light → strong) and dashed lines mark each configured threshold — drag the sliders to move them.
Top-risk patients
Sampled top-25 across groups. Click into any patient for full attribution. Hover any group chip to see its definition.
| Patient | Score | Group | Top driver | |
|---|---|---|---|---|
Ressie Abernathy MRN-2605-06C1-91D5 | 94 | J· Stage IV / progressing | Active chemotherapy — Gemcitabine 1000 MG/M2 | |
Grover Feest MRN-DE64-7715-767F | 87 | I· On treatment | Active chemotherapy — Oxaliplatin 85 MG/M2 | |
Tina Hernandez MRN-FC91-5D0F-DEF6 | 70 | G· EUS surveillance | Comorbidities | |
Daren Lakin MRN-96DE-E0DB-A8BE | 62 | F· Cyst / lesion confirmed | Pancreatic cyst | |
Geraldine Wiza MRN-B3C4-9173-F07B | 55 | E· Imaging ordered | Comorbidities | |
Ike Thiel MRN-CDBF-DD5F-3EAA | 45 | D· Elevated risk | Comorbidities | |
Justus Anderson MRN-81C8-FBD7-91F4 | 94 | J· Stage IV / progressing | Progressive disease (RECIST PD) | |
Kane Hettinger MRN-E4CE-9CDC-D4F4 | 87 | I· On treatment | Active chemotherapy — Oxaliplatin 85 MG/M2 | |
Marisol Macejkovic MRN-0B29-8EFE-23FD | 70 | G· EUS surveillance | Comorbidities | |
Mariela Donnelly MRN-0747-745A-4B83 | 62 | F· Cyst / lesion confirmed | Comorbidities | |
Greta Bruen MRN-032B-EBB6-025E | 55 | E· Imaging ordered | Comorbidities | |
Marc Gottlieb MRN-9A13-3D65-6392 | 45 | D· Elevated risk | Comorbidities | |
Morton Auer MRN-1A31-B01E-7597 | 94 | J· Stage IV / progressing | Progressive disease (RECIST PD) | |
Raegan Kuphal MRN-F44E-B8B0-841A | 87 | I· On treatment | Active chemotherapy — Oxaliplatin 85 MG/M2 | |
Mallory Balistreri MRN-B1C8-96CA-6A52 | 70 | G· EUS surveillance | Comorbidities | |
Lexi Cronin MRN-4A32-7A44-C3FE | 62 | F· Cyst / lesion confirmed | Comorbidities | |
Russ Hessel MRN-63BD-3503-2EE2 | 55 | E· Imaging ordered | Jaundice presentation | |
Antoinette Kuvalis MRN-E116-3028-7E1B | 45 | D· Elevated risk | Comorbidities | |
Jeanette Bailey MRN-43D0-7A97-7261 | 94 | J· Stage IV / progressing | Active chemotherapy — Gemcitabine 1000 MG/M2 | |
Kenyatta Lemke MRN-FD5C-2960-A986 | 87 | I· On treatment | Active chemotherapy — Cisplatin 50 MG | |
Derek Ryan MRN-8012-70D4-8A77 | 70 | G· EUS surveillance | Comorbidities | |
Torey Leffler MRN-62E5-9E78-64F0 | 62 | F· Cyst / lesion confirmed | Pancreatic cyst | |
Kelvin Schiller MRN-A6E6-5A05-EF98 | 55 | E· Imaging ordered | Comorbidities | |
Guy Jerde MRN-6421-6F90-4AEA | 45 | D· Elevated risk | Comorbidities | |
Kenyon Bailey MRN-D71E-B3AC-46B3 | 94 | J· Stage IV / progressing | Progressive disease (RECIST PD) |
PANDA risk-group key
Scoring engine is deterministic and decomposable. Weights are inline insrc/lib/data/risk-engine-queries.tsand intended to be calibrated against Research Hub outcomes — that feedback loop is the next major build. Per spec module 5 §"Continuous score recalibration using downstream outcomes".